about
Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?The zebrafish as a model for studying neuroblastomaBAG1: the guardian of anti-apoptotic proteins in acute myeloid leukemia.Neuroblastoma treatment in the post-genomic era.Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.Expression Profiling of Circulating Microvesicles Reveals Intercellular Transmission of Oncogenic Pathways.MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia.ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.Screening of novel genetic aberrations in pediatric acute myeloid leukemia: a report from the AIEOP AML-2002 study group.TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy.Targeting BAG-1: a novel strategy to increase drug efficacy in acute myeloid leukemia.A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.CREB engages C/EBPδ to initiate leukemogenesis.Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.Choline Kinase Alpha Inhibition by EB-3D Triggers Cellular Senescence, Reduces Tumor Growth and Metastatic Dissemination in Breast CancerExploring Cancer Cell Behavior In Vitro in Three-Dimensional Multicellular Bioprintable Collagen-Based HydrogelsImportance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemiaLIN28B increases neural crest cell migration and leads to transformation of trunk sympathoadrenal precursorsCorrection to: LIN28B increases neural crest cell migration and leads to transformation of trunk sympathoadrenal precursorsCalcium phosphate scaffolds with defined interconnecting channel structure provide a mimetic 3D niche for bone marrow metastasized tumor cell growth
P50
Q26739760-8B326598-2B9B-4E90-BB2A-56B40784C4B9Q28070309-FCB0EA9E-C0C7-4F70-A15F-F5392B8C2A39Q34053504-13429720-48D7-4A91-B1FD-6C10CB6EFEBAQ37633731-BA48EBDE-7432-4BCE-B056-DD0F4D41A772Q38806238-A29CA1D3-F7A5-4208-94FE-4544AED75FF3Q38959446-832661CD-285E-4881-A49C-8B4C9F95EA9EQ39008746-B2B07AD2-185C-470A-A2DA-0227A83766D1Q42265722-BE47B73A-5BEA-4DF0-BD24-7E320219D747Q47817382-0E78B93C-99AF-495D-9F36-38DA82878211Q49866304-85FABFC0-0B58-4649-B821-DAF72A449AF0Q51029263-E088E2EC-4FE0-442F-B730-294BCCDEF1C5Q52562884-7DCF2BB6-4450-44A3-87D6-8C3B7115BCB5Q52671045-701B9382-6240-4BAE-B35D-A567A2DE721EQ54113343-413443EE-E083-4F99-92F5-9C001AA1C8E8Q58579238-CFCCD2CA-619D-4D76-9F49-6A897320AF24Q64243511-F115CE0D-3727-4E35-9486-A2C0202ECC45Q80501673-524AE83C-EF9A-46AE-BD4F-65B7DC0D09D9Q90641474-CC86A098-CB1F-46CD-A69F-1F7A3834F801Q91330021-A3CE57C6-13CE-4407-A03A-B7FE26677720Q91851332-EE6242BF-1746-4DAB-B4F3-610E54E675A8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sanja Aveic
@ast
Sanja Aveic
@en
Sanja Aveic
@es
Sanja Aveic
@nl
Sanja Aveic
@sl
type
label
Sanja Aveic
@ast
Sanja Aveic
@en
Sanja Aveic
@es
Sanja Aveic
@nl
Sanja Aveic
@sl
prefLabel
Sanja Aveic
@ast
Sanja Aveic
@en
Sanja Aveic
@es
Sanja Aveic
@nl
Sanja Aveic
@sl
P214
P106
P1153
20435413800
P214
P31
P396
IT\ICCU\CFIV\290354
P496
0000-0002-3886-4360
P569
1980-01-01T00:00:00Z
P7859
viaf-307347728